CN105188694B - 用于治疗疼痛的钠通道调节剂 - Google Patents

用于治疗疼痛的钠通道调节剂 Download PDF

Info

Publication number
CN105188694B
CN105188694B CN201480014410.XA CN201480014410A CN105188694B CN 105188694 B CN105188694 B CN 105188694B CN 201480014410 A CN201480014410 A CN 201480014410A CN 105188694 B CN105188694 B CN 105188694B
Authority
CN
China
Prior art keywords
compound
pain
chloro
formula
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480014410.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105188694A (zh
Inventor
奥尔加·巴比奇
罗伯特·Z·罗
王艳林
大卫·J·帕林格
斯里尼瓦桑·P·文卡塔查兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromocell Corp
Original Assignee
Chromocell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromocell Corp filed Critical Chromocell Corp
Publication of CN105188694A publication Critical patent/CN105188694A/zh
Application granted granted Critical
Publication of CN105188694B publication Critical patent/CN105188694B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201480014410.XA 2013-03-15 2014-03-13 用于治疗疼痛的钠通道调节剂 Expired - Fee Related CN105188694B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787618P 2013-03-15 2013-03-15
US61/787,618 2013-03-15
PCT/US2014/025809 WO2014151472A1 (en) 2013-03-15 2014-03-13 Sodium channel modulators for the treatment of pain

Publications (2)

Publication Number Publication Date
CN105188694A CN105188694A (zh) 2015-12-23
CN105188694B true CN105188694B (zh) 2018-07-31

Family

ID=51580969

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480014410.XA Expired - Fee Related CN105188694B (zh) 2013-03-15 2014-03-13 用于治疗疼痛的钠通道调节剂

Country Status (16)

Country Link
US (1) US10179781B2 (enExample)
EP (1) EP2968234B1 (enExample)
JP (1) JP6449845B2 (enExample)
KR (1) KR20150131254A (enExample)
CN (1) CN105188694B (enExample)
AU (1) AU2014234105B2 (enExample)
BR (1) BR112015022096A8 (enExample)
CA (1) CA2900604A1 (enExample)
ES (1) ES2687481T3 (enExample)
HK (1) HK1219060A1 (enExample)
IL (1) IL242564A0 (enExample)
MX (1) MX363680B (enExample)
MY (1) MY188139A (enExample)
PH (1) PH12015501740A1 (enExample)
RU (1) RU2669367C2 (enExample)
WO (1) WO2014151472A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014005297A (es) 2011-10-31 2014-09-11 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos.
CA2855019A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
MX2015000164A (es) 2012-07-06 2015-08-12 Genentech Inc Benzamidas n-sustituidas y metodos para usarlas.
EP2968280A4 (en) 2013-03-14 2016-08-10 Genentech Inc SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF
KR20150131254A (ko) 2013-03-15 2015-11-24 크로모셀 코포레이션 통증 치료를 위한 소듐 채널 조절자
WO2014144545A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
WO2015038533A2 (en) * 2013-09-10 2015-03-19 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3193610A4 (en) * 2014-09-09 2018-04-04 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes
CN104710379B (zh) * 2015-03-09 2017-01-18 华南理工大学 一种bms‑191011的合成方法
JP2018520107A (ja) 2015-05-22 2018-07-26 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
CR20180242A (es) 2015-09-28 2018-08-10 Genentech Inc Compuestos terapéuticos y sus métodos de uso
CA3090492C (en) 2015-10-07 2023-02-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Crmp2 sumoylation inhibitors and uses thereof
WO2017091592A1 (en) 2015-11-25 2017-06-01 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
TW201726637A (zh) 2015-12-18 2017-08-01 默沙東藥廠 對電位閘控鈉通道具選擇活性之羥基烷基胺－及羥基環烷基胺－取代之二胺－芳基磺胺化合物
WO2017172802A1 (en) 2016-03-30 2017-10-05 Genentech, Inc. Substituted benzamides and methods of use thereof
RU2019114964A (ru) 2016-10-17 2020-11-17 Дженентек, Инк. Терапевтические средства и способы их применения
US10793550B2 (en) 2017-03-24 2020-10-06 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
WO2019165290A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
WO2019200369A1 (en) * 2018-04-13 2019-10-17 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
WO2019217822A1 (en) * 2018-05-11 2019-11-14 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
SG11202101632XA (en) 2018-09-10 2021-03-30 Kaken Pharmaceutical Co Ltd Novel heteroaromatic amide derivative and medicine containing same
US20220125784A1 (en) * 2019-02-04 2022-04-28 Simon Fraser University Methods and compounds for inhibition of inactivation of voltage-gated sodium channels
CN112759559B (zh) * 2019-11-06 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012004706A2 (en) * 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905971A (en) * 1971-03-29 1975-09-16 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
ES2311920T3 (es) 2001-03-14 2009-02-16 Grunenthal Gmbh Tiazolopirimidinas sustituidas como analgesicos.
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
RU2006107211A (ru) * 2003-08-08 2007-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Композиции, полезные в качестве ингибиторов потенциалозависимых натриевых каналов
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
US7449477B2 (en) 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
ES2505090T3 (es) 2004-05-07 2014-10-09 Amgen Inc. Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer
JP4056081B1 (ja) * 2004-07-23 2008-03-05 ファイザー・インク ピリジン誘導体
AU2005300150A1 (en) 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
CA2634743C (en) 2005-12-23 2014-07-29 Zealand Pharma A/S Modified lysine-mimetic compounds
WO2009012242A2 (en) * 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
WO2009012241A1 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
HRP20150355T1 (hr) 2009-01-12 2015-06-19 Pfizer Limited Sulfonamidni derivati
JP5685203B2 (ja) 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
JP2013525368A (ja) 2010-04-23 2013-06-20 キネタ・インコーポレイテツド 抗ウイルス性化合物
EP2590957B1 (en) 2010-07-09 2014-11-12 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
US20120185956A1 (en) 2011-01-18 2012-07-19 Gingras Jacinthe Global nav1.7 knockout mice and uses
EP2744805A1 (en) 2011-08-17 2014-06-25 Amgen Inc. Heteroaryl sodium channel inhibitors
HK1200114A1 (en) 2011-09-21 2015-07-31 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
CA2855019A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
CA2890897A1 (en) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System Inhibition of hif-2.alpha. heterodimerization with hif 1.beta. (arnt)
KR20150131254A (ko) 2013-03-15 2015-11-24 크로모셀 코포레이션 통증 치료를 위한 소듐 채널 조절자
US9908845B2 (en) 2013-09-09 2018-03-06 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
WO2015038533A2 (en) 2013-09-10 2015-03-19 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012004706A2 (en) * 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds

Also Published As

Publication number Publication date
EP2968234A1 (en) 2016-01-20
MX2015011907A (es) 2016-05-16
WO2014151472A1 (en) 2014-09-25
JP2016512844A (ja) 2016-05-09
MY188139A (en) 2021-11-23
IL242564A0 (en) 2016-02-29
AU2014234105A1 (en) 2015-09-03
AU2014234105B2 (en) 2019-01-03
CA2900604A1 (en) 2014-09-25
CN105188694A (zh) 2015-12-23
RU2015133310A (ru) 2017-04-20
PH12015501740A1 (en) 2015-10-19
BR112015022096A8 (pt) 2019-11-26
RU2015133310A3 (enExample) 2018-02-28
EP2968234B1 (en) 2018-06-27
HK1219060A1 (zh) 2017-03-24
JP6449845B2 (ja) 2019-01-09
MX363680B (es) 2019-03-29
EP2968234A4 (en) 2016-10-12
US20160046617A1 (en) 2016-02-18
ES2687481T3 (es) 2018-10-25
BR112015022096A2 (pt) 2017-07-18
KR20150131254A (ko) 2015-11-24
US10179781B2 (en) 2019-01-15
RU2669367C2 (ru) 2018-10-11

Similar Documents

Publication Publication Date Title
CN105188694B (zh) 用于治疗疼痛的钠通道调节剂
CN105611923B (zh) 用于治疗疼痛和糖尿病的钠通道调节剂
CN107001283B (zh) Flt3受体拮抗剂
JP2012521429A (ja) 疼痛治療用のｐ２ｘ３受容体アンタゴニスト
CN110128415B (zh) 用作免疫调节剂的吲哚啉类化合物及其制备方法
BR112013026137B1 (pt) pirimidinil-pirróis substituídos ativos como inibidores da quinase
JP2019512009A (ja) スルホニルウレアおよび関連化合物ならびにこれらの利用
JP7170996B2 (ja) スルホンアミド誘導体またはその薬学的に許容される酸付加塩
BR112015027114B1 (pt) Compostos inibidores seletivos de histona desacetilase e seu uso
CN103391718A (zh) 取代的吡啶酮-吡啶基化合物
CN108602807A (zh) 杂环磺酰胺衍生物及含有其的药物
JP2017527573A (ja) 糖尿病の治療用の選択的ＮａＶ１．７阻害剤
US8530453B2 (en) Compounds and methods for the treatment of pain and other diseases
WO2005118543A1 (ja) キナーゼ阻害薬およびその用途
JP7527039B2 (ja) Ｇｌｕｔ１欠損症症候群の治療に使用するためのイソキノリン誘導体
HK1224572A1 (en) Sodium channel modulators for the treatment of pain and diabetes
TW202513551A (zh) Trek(twik相關的k+通道)通道功能的抑制劑
WO2014190872A1 (zh) 一种含硒化合物及其医药用途
WO2006090698A1 (ja) キナーゼ阻害薬およびその用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1219060

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180731

Termination date: 20200313

CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1219060

Country of ref document: HK